San Francisco, California – July 22, 2025 – Avvio Medical, Inc., a company dedicated to revolutionizing the treatment of urinary stones, is excited to announce that the American Medical Association (AMA) has officially published the early release of a new Category III CPT code for Avvio’s novel kidney stone treatment system.
Effective January 1, 2026, CPT code 0991T will be used by healthcare providers and facilities nationwide to report procedures utilizing Avvio Medical’s innovative technology. The new code, which reflects the final nomenclature approved by the AMA, marks a significant milestone in Avvio’s journey to expand patient access, improve care, and streamline reimbursement for its groundbreaking approach.
“The introduction of a dedicated CPT code for our technology demonstrates the clinical importance of our ureteral stone solution,” said Paul Molloy, CEO, Avvio Medical. “This achievement will help ensure that physicians and health systems can more easily offer our therapy to patients while benefiting from clear and accurate billing processes.”
Avvio worked with expert reimbursement strategy consultants, Jeffrey Dann M.D and PRIA Healthcare to support the code application process and overall market access planning.
The announcement was made public as part of the AMA’s official Category III CPT Code Early Release, available here.
What This Means
- CPT 0991T will take effect January 1, 2026.
- The new code reflects important progress toward bringing Avvio’s technology to patients and
- This development highlights Avvio’s commitment to advancing access and innovation in kidney stone care.
About the Enhanced Lithotripsy System (ELS)
The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy, enabling kidney stone treatments outside the traditional operating room and into more accessible outpatient settings like ambulatory surgery centers (ASCs), office-based labs (OBLs), and cystoscopy suites. The system delivers a single, minimally invasive therapy without the need for general anesthesia, fluoroscopy, intra-operative imaging, or costly capital equipment. By reducing procedural complexity and resource requirements, ELS supports wider patient access, improves care delivery efficiency, and offers meaningful clinical, economic, and health equity benefits.
About Avvio Medical
Avvio Medical is a privately held company which aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of urinary stones. The company’s initial technology is designed to offer patients and healthcare professionals a fast, minimally invasive solution for treating urinary stone disease in various clinical or outpatient settings, eliminating the routine need for anesthesia or X-ray imaging.
Media Contact:
Paul Molloy
Chief Executive Officer
Avvio Medical, Inc.
Email: paul.molloy@avviomed.com
Tel: (415) 887-2037
MKT0018, Rev. A